Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

View:
Post by MoMoneySean on Mar 28, 2016 7:29am

Yosprala

https://www.ottawacitizen.com/business/cnw/release.html?rkey=20160328C6833&filter=5609
Comment by Floridas2000 on Mar 28, 2016 9:12am
That's encouraging - looks like it will start to take off today.
Comment by kuatolives on Mar 28, 2016 9:17am
So help me out here, was pozen issued a PDUFA last time as well, or is this net new territory? ie, are we passed the aspirin supplier problem? 
Comment by Floridas2000 on Mar 28, 2016 9:24am
No they haven't passed the supplier problem.  Pozen has been at this stage before but it was done fairly quickly so I'm guessing that's the positive point.  
Comment by GoldenDilemma on Mar 28, 2016 9:27am
This is encouraging news. I like how a date has been set. It seems like the process has been guided well thus far with Adams. Approval before date will be as good as it can get.
Comment by kuatolives on Mar 28, 2016 9:40am
Hopefully Mr. Market now has a base to start turning sentiment in our favor for a change. Yosprala approval, a couple of deals by the end of the summer, and we might be doing well. (again).
Comment by Bigboyone on Mar 28, 2016 9:49am
Awesome!! Our Tribute shares now worth 55 cents US...
Comment by Bigboyone on Mar 28, 2016 11:35am
What makes it more frustrating is on any bit of postive news, the funds are still heading for the Exits. I would say this is "Bearish and not "Bullish" for Aralez, 500k plus shares and counting for a few hours in..(Today Monday) Looks like, Mid- September is the big announcement... I dread to say what price who will be if the FDA give another Yosprala, non Approval, Something to ...more  
Comment by Floridas2000 on Mar 30, 2016 1:03pm
It is frustrating to know that TRX on his own would've greatly outperformed the current Aralez, even with the specialty pharma melt down.  TRX was looking at improving at multiples YOY, at this point of time I can't see Aralez doing anything like that.  I thought it might double or triple by year end since it was beaten up but I will be happy with 50% the way they're doing ...more  
Comment by kuatolives on Mar 30, 2016 5:31pm
Yeah I never understood the whole smaller piece of a (potentially) bigger pie tradeoff as far as Tribute went. As of today, I don't think there are Tribute holders who didn't at best breal evem or worse lose money (Way to look out for your investors Mr. Harris).  The merger was all about Harris and Langille cashing out their free shares so.... just goes to show you you can still go ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities